Cytek Biosciences (CTKB) Amortization of Deferred Charges (2022 - 2026)

Cytek Biosciences' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $948000.0 for Q1 2026.

• Quarterly Amortization of Deferred Charges fell 6.05% year-over-year to $948000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 22.94% YoY) and the FY2025 annual result came in at $4.4 million, up 34.11% from the prior year.
• Amortization of Deferred Charges was $948000.0 for Q1 2026 at Cytek Biosciences, down from $1.1 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.1 million in Q4 2025 and bottomed at $672000.0 in Q2 2024.
• A 5-year average of $880647.1 and a median of $800000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2023 — Amortization of Deferred Charges slipped 28.01% — and 2025, when it jumped 63.39%.
• Cytek Biosciences' Amortization of Deferred Charges stood at $1.1 million in 2022, then declined by 28.01% to $794000.0 in 2023, then increased by 11.71% to $887000.0 in 2024, then gained by 29.31% to $1.1 million in 2025, then fell by 17.35% to $948000.0 in 2026.
• Business Quant data shows CTKB's Amortization of Deferred Charges at $948000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.